Bisphosphonates and osteonecrosis: potential treatment or serious complication?
They are commonly used to treat osteoporosis and other diseases that involve osteoclast-mediated bone resorption, including Paget's disease and multiple myeloma. Their use in treating osteonecrosis of the femoral head has been studied and theoretically holds promise. There are complications associated with these medications, however, including the development of osteonecrosis in the jaw.
Goytia
Robin N
RN
Johns Hopkins Orthopaedics at Good Samaritan Hospital, 5601 Loch Raven Boulevard, Professional Office Building, Suite G-1, Baltimore, MD 21239, USA.
Salama
Andrew
A
Khanuja
Harpal S
HS
D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001862:Bone Resorption / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D001842:Bone and Bones / Q000737:chemistry / Q000187:drug effects; D004164:Diphosphonates / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D010020:Osteonecrosis / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D012307:Risk Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates